How Does It Work? PrEP drugs like Truvada and Descovy belong to a class of antiviral drugs called nucleoside reverse transcriptase inhibitors (NRTIs). This means they stop HIV from making copies. They do this by blocking the protein called reverse transcriptase—this protein is needed for HI...
Integrase Inhibitors These drugs stop HIV from making copies of itself by blocking a key protein that allows the virus to put its DNA into the healthy cell's DNA. They're also called integrase strand transfer inhibitors (INSTIs). Bictegravir or BIC (combined with other drugs as Biktarvy)...
J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646–650 (2000). Article CAS PubMed Google Scholar Summa, V. et al. Discovery of raltegravir. A potent, selective orally bioavailable HIV-integrase inhibitor for the ...
Moreover, these two systems (DD-FKBP/Shield-1 and ecDHFR/TMP) can be used orthogonally, and both inhibitors do not seem to have any major side effects in animal models. The cell specificity in vivo could be achieved by using tissue-specific promoters; further, protein accumulation...
Tolerability of integrase inhibitors in a real-life setting J Antimicrob Chemother, 72 (2017), pp. 1752-1759 CrossrefView in ScopusGoogle Scholar 20 WDF Venter, M Moorhouse, S Sokhela, et al. Dolutegravir plus two different prodrugs of Tenoforvir to treat HIV N Engl J Med, 381 (2019),...
Computational techniques have provided the field of drug discovery with enormous advances over the last decades. The development of methods covering dynamical aspects in protein–ligand binding is currently leading computer-aided drug design to new level
NNRTIs aside, thefirst-line treatment approachof HIV-2 is similar to that of HIV-1 and typically consists of two nucleoside reverse transcriptase inhibitors (NRTIs) and one integrase strand transfer inhibitor (INSTI), such as: bictegravir ...
More needs to be learnt about the interactions between anti-TB and ARV drugs, especially between rifampicin and new integrase inhibitors, such as dolutegravir which is increasingly being promoted as a component of first-line ART [47]. The optimal ways to improve treatment outcomes in patients ...
HIV-1 takes advantage of the cellular cytoskeleton at various steps in its replication cycle, most intriguingly is the involvement of the actin machinery during the entry process. However, knowledge is limited at other steps of the replication cycle and future work will be required to shed light...